Results 131 to 140 of about 33,519 (179)
Some of the next articles are maybe not open access.
Extramedullary acute myelogenous leukemia
Blood Reviews, 2016Extramedullary leukemia (EM AML), also known as myeloid sarcoma, is a rare manifestation of acute myelogenous leukemia and often accompanies bone marrow involvement. EM AML is diagnosed based on H&E stains with ancillary studies including flow cytometry and cytogenetics.
Melhem, Solh +4 more
openaire +2 more sources
Current Problems in Pediatric and Adolescent Health Care, 2002
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +2 more sources
~ cute myelogenous leukemia (AML) is characterized by the overproduction of immature myeloid cells in the bone marrow, which leads to bone marrow failure and infiltration of organs such as the liver and spleen. During the past several decades progress has been made in our knowledge of the biologic study and treatment of AML.
openaire +2 more sources
Hypokalemia in Acute Myelogenous Leukemia
Southern Medical Journal, 1983Forty-two patients with acute myelogenous leukemia or one of its variants were studied at diagnosis to determine the incidence and cause(s) of hypokalemia. Forty-three percent of patients were hypokalemic, and an inappropriate renal loss of potassium was noted.
M C, Perry, J H, Bauer, M, Farhangi
openaire +2 more sources
Acute Myelogenous Leukemia and Hepatitis
Annals of Internal Medicine, 1980Excerpt To the editor: Barton and Conrad reported in the February 1979 issue (1) that post-transfusion hepatitis developing in patients with acute myelogenous leukemia may improve the prognosis.
E, Cacciola, R, Giustolisi
openaire +2 more sources
Prognosis of Acute Myelogenous Leukemia
Annals of Internal Medicine, 1982Excerpt To the editor: Barton and Conrad reported in the February 1979 issue (1) an association of elevation of the aspartate transaminase (AST) levels with improved prognosis of acute myelogenous ...
J J, Lahuerta-Palacios +3 more
openaire +2 more sources
The Management of Acute Myelogenous Leukemia
Medical Clinics of North America, 1975Although definite improvement in the treatment of acute myelogenous leukemia has taken place, the outlook for patients remains grim. The current aggressive approach to treatment, entailing a program of chemotherapy which almost invariably produces bone marrow aplasia and considerable toxicity, has been the subject of some controversy. Selected aspects
openaire +2 more sources
Therapy of acute myelogenous leukemia
Cancer, 1978There has been a rapid improvement in the overall prognosis for patients with acute myelogenous leukemia. The major determinant for this change is a progressive increase in the frequency of inducing complete hematological and clinical remissions from low levels to levels in excess of 50% of patients.
E J, Freireich +5 more
openaire +2 more sources
Progress in Acute Myelogenous Leukemia
Annals of Internal Medicine, 1984There has been substantial recent progress in the treatment of acute myelogenous leukemia (AML). Intensive induction chemotherapy with cytosine arabinoside and daunorubicin with or without 6-thioguanine will induce remission in over 70% of patients, with median remission of 1-2 years in most series.
openaire +3 more sources
Immunotherapy for Acute Myelogenous Leukemia
2015One hundred and seven untreated patients with acute myelogenous leukemia (AML) were admitted to St. Bartholomew's Hospital between the 10th October 1970 and the 31st January 1973. Before receiving drugs to induce remission they were allocated alternatively into 2 groups to decide their remission treatment, a group to receive chemotherapy alone and a ...
R L, Powles +5 more
openaire +2 more sources
2016
After a peak during the first 2 years of life, the incidence of acute myelogenous leukemia (AML) is low (five per million 5- to 9-year-olds per year in the United States) until after 9 years of age, when it slowly increases during adolescence and adulthood (to nine per million per year among 15- to 19-year-olds in the United States).
Ursula Creutzig +2 more
openaire +1 more source
After a peak during the first 2 years of life, the incidence of acute myelogenous leukemia (AML) is low (five per million 5- to 9-year-olds per year in the United States) until after 9 years of age, when it slowly increases during adolescence and adulthood (to nine per million per year among 15- to 19-year-olds in the United States).
Ursula Creutzig +2 more
openaire +1 more source